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Abstract
The nuclear receptor superfamily of ligand-activated transcription factors plays a central role in the regulation of cellular
responses to chemical challenge. Nuclear receptors are activated by a wide range of both endogenous and exogenous
chemicals, and their target genes include those involved in the metabolism and transport of the activating chemical. Such
target gene activation, thus, acts to remove the stimulating xenobiotic or to maintain homeostatic levels of endogenous
chemicals. Given the dual nature of this system it is important to understand how these two roles are balanced, such that
xenobiotics are efficiently removed while not impacting negatively on homeostasis of endogenous chemicals. Using DNA
microarray technology we have examined the transcriptome response of primary rat hepatocytes to two nuclear receptor
ligands: Pregnenalone-16a-carbonitrile (PCN), a xenobiotic PXR agonist, and lithocholic acid, an endogenous mixed PXR/
VDR/FXR agonist. We demonstrate that despite differences in the profile of activated nuclear receptors, transcriptome
responses for these two ligands are broadly similar at lower concentrations, indicating a conserved general response.
However, as concentrations of stimulating ligand rises, the transcriptome responses diverge, reflecting a need for specific
responses to the two stimulating chemicals. Finally, we demonstrate a novel feed-back loop for PXR, whereby ligand-
activation of PXR suppresses transcription of the PXR gene, acting to attenuate PXR protein expression levels at higher
ligand concentrations. Through in silico simulation we demonstrate that this feed-back loop is an important factor to
prevent hyperexpression of PXR target genes such as CYP3A and confirm these findings in vitro. This novel insight into the
regulation of the PXR-mediated regulatory signal networks provides a potential mechanistic rationale for the robustness in
steroid homeostasis within the cell.
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Introduction
Within biological systems there is a requirement for robustness,
defined as the ability of that biological system to continue to carry
out its fundamental tasks [1]. Perfect robustness within a network
is unlikely to occur unless the network fulfils some very specific
criteria [2], and indeed such perfect robustness is probably
relatively rare in biological systems. However, the use of feed-back
and feed-forward mechanisms allows systems to adapt to
alterations in environmental conditions, thus achieving quasi-
robustness. With respect to drug metabolism, the processes’ of
adsorption, distribution, metabolism and excretion (ADME)
following chemical exposure are targeting at reducing the level
of the challenging chemical back to the pre-challenge state, i.e.
zero. This, in itself, is a relatively simple aim; however, as these
same ADME processes’ also control the fate of endogenous
chemicals within the body, any alteration in ADME processes
caused in response to challenge by external chemicals will
potentially impact upon these endogenous processes, potentially
leading to pathophysiology [3], or on other xenobiotics, potentially
resulting in clinically relevant drug-drug interactions [4]. There is
thus a need for balance within the ADME system, such that
central body functions are not overtly impacted by xenobiotic-
mediated alterations (quasi-robustness), yet the system is still able
to respond effectively to xenobiotic challenge, or extreme
fluctuations in endogenous chemical levels suggestive of patho-
physiology (sensitivity). This balance is achieved through three,
interconnected systems: First, promiscuity within the ligand
specificity for transporters and drug metabolizing enzymes ensures
that for any given chemical, whether it is endogenous or
exogenous in origin, several complimentary systems can mediate
the efficient removal of the stimulating chemical [5,6,7,8,9].
Second, activation of ADME pathways is closely coupled with the
activation of protective mechanisms that remove toxic damage
elicited by stimulating chemicals should it occur before the
chemical can be safely removed [10,11]. Third, impact of
chemicals on ADME pathways are subject to complex feed-back
and feed-forward loops at the nuclear receptor level, coordinating
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16703expression levels of both metabolic and transporter proteins with
their requirement to handle fluctuating chemical levels
[7,12,13,14]. These latter networks have become an area of
intense study, as their dysfunction may underlie some of the
observed adverse effects observed following chemical exposures. In
addition, manipulation of these networks represents an exciting
novel therapeutic area for the treatment of endogenous chemical
metabolism dysfunction [15,16].
The pregnane X-receptor (PXR, NR1I2) is an important
regulator of a number of target genes involved in the metabolism
of xenobiotics, including both metabolic enzymes and drug
transporters [17,18]. It is activated by a wide range of xenobiotics
[19], and is itself regulated by a number of other nuclear receptors
[14,20,21], highlighting it as an important node in the regulatory
signal network concerned with body responses to xenobiotics. In
addition to this established role as a xenosensing nuclear receptor
it is important to note that PXR target genes are also important in
a number of physiological functions, including haem, bile and
cholesterol synthesis [22]: It is therefore pertinent to ask how
PXR-mediated effects on xenobiotic and endobiotic metabolism
are balanced to achieve both the sensitivity to xenobiotic
challenge, but allow robustness in endogenous steroid metabolism.
To study this, we have examined the target gene set activated by
two nuclear receptor agonists, lithocholic acid (LCA) and
pregnenalone-16a-cabonitrile (PCN). LCA is an endogenous bile
acid, which acts as an agonist for PXR, the farnesoid X-receptor
(FXR) and the vitamin D receptor (VDR), whereas PCN is an
exogenous antiglucocorticoid, which acts solely as a PXR agonist.
Using DNA microarray technology we examine the hypothesis
that differential nuclear receptor regulation by the two chemicals
allows an efficient response to the stimulating chemical, while
minimising impact on endogenous steroid metabolism.
Results
Differential activation of classic target genes for PXR, VDR
and FXR target gene expression by LCA and PCN in
primary rat hepatocytes
Both PCN and LCA have been reported as PXR agonists [23],
while LCA is also a known agonist for FXR [24] and VDR [25],
with the relative EC50s for target gene activation suggesting an
affinity of VDR.FXR.PXR. To confirm that this differential
induction profile primary rat hepatocytes were grown in a sandwich
cell culture system as described in Howe et al [26]; growth of
hepatocytes between two layers of collagen permits correct
polarisation of the cells and formation of functional bile cannaliculi,
which may be important when studying the action of bile salts such
asLCA. Todeterminea relative order ofpotency,we firstexamined
the transcript levelsof classical PXR, VDRand FXRtargetgenes in
response to 48 hours exposure to either LCA or PCN: For this
purpose CYP3A1, GSTA2 and ABCC2 represent PXR target
genes [23], CYP24 and KLK6 represent VDR target genes [25],
while Fibrinogen b and UGT2B4 represent FXR-target genes [24].
As can be seen from Figure 1, the PXR target genes CYP3A1,
GSTA2 and ABCC2 all demonstrate significant dose-dependent
increases in transcript levels in response to both PCN and LCA,
although with a generally lower potency with LCA (Figure 1a). In
comparison, the VDR-target genes CYP24 and KLK6 are only
activated byLCA(Figure 1b), as isthecase fortheFXRtarget genes
Fibrinogen b and UGT2B4 (Figure 1c). The relative potency of
LCA as agonist for PXR, FXR and VDR can be estimated through
the EC50s of induction for their respective target genes (Table 1),
and is consistent with the published literature, being
VDR.FXR..PXR.
PCN and LCA activate differential nuclear receptor
expression patterns
One level of co-ordination of cellular responses to chemical
challenge is the control of nuclear receptor transcription and/or
activity by other nuclear receptors. To examine this, we measured
PCN and LCA-mediated effects on nuclear receptor expression
levels within primary rat hepatocytes. As can be seen from
Figure 2, both PCN and LCA caused a dose-dependent
suppression of PXR transcript levels (Figure 2a); in addition, this
suppression was confirmed at the protein level, with PCN eliciting
a marked decrease in PXR protein levels, and LCA exposure
eliciting a smaller decrease (Figure 2b). In contrast, the expression
of VDR and FXR appeared unaffected by either PCN or LCA
exposure. We also examined the expression of the small-
heterodimer partner (SHP), which can heterodimerise with
activated receptors and prevent transactivation of DNA as it lacks
a DNA binding domain [27]. SHP expression was unaffected by
the PXR agonist PCN, but was significantly increased following
exposure of rat hepatocytes to LCA (EC50 =12.766.5 mM),
consistent with its known role in response to bile acids [28].
PCN- and LCA-mediated transcriptome changes
Following the demonstration that both PCN and LCA activate
classical target genes for PXR (PCN and LCA), FXR (LCA only)
and VDR (LCA only), we next examined the total transcriptome
response to these agents. Exposure of sandwich cultured
hepatocytes to varying concentrations of either LCA or PCN for
48 hours resulted in a dose-dependent increase in the total
number of genes activated, with similar total numbers of genes
affected by both chemicals (Table 2). To further examine the
response to either agent, and detect the major variables between
the two datasets, multivariate statistical analysis was undertaken.
Initially, heirachical cluster analysis using centroid linkage and an
uncentered correlation metric was performed, producing the
heatmap seen in Figure 3a. The heatmap demonstrates a
clustering of higher dose (5 and 10 mM) PCN-treated hepatocytes,
with a second cluster containing the low dose (1 mM) PCN, plus
the higher dose (50 and 100 mM) LCA samples: This latter cluster
presumably reflects the similar PXR-mediated activation of target
gene sets by these treatments, and is consistent with the notion of
LCA as a lower potency agonist than PCN.
Next, principle component analysis (PCA) was used to examine
the drivers for variability within the dataset. Figure 3b demon-
strates that whereas the initial trajectories of the plots are the same,
being primarily described by principal component 1, as the dose
increases the trajectories separate along principal component 2.
To further examine the divergence of dose response trajectories for
PCN and LCA, the PCA eigenvectors associated with both
principle components were analysed. PC1, which accounts for
38% of the total variation, has twenty eigengenes that drive the
variability along this axis (Table 3). In general, these eigengenes
are involved in ADME processes, either being metabolic enzymes
or transport proteins, and the majority of these have their
zexpression increased by both LCA and PCN; a selection of these
eigengenes were analysed by Q-PCR, and the results are presented
in Figure 4, demonstrating that these eigengenes are altered by
both PCN and LCA exposures.
PC2, which accounts for 16% of the variability within the
dataset, comprises 6 eigengenes (Table 3), including metallothio-
nein 1a (MT-1) and metallothionein 2 (MT-2), with eigen values of
0.46 and 0.34 respectively. These changes were confirmed by Q-
PCR, demonstrating that these eigengenes are altered by LCA,
but not PCN, exposures (Figure 5a). The expression of MT-3 was
also examined, demonstrating it is expressed at very low levels in
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MTs in response to pro-oxidants [29], the expression of other
oxidative stress response genes, the glutathione peroxiodase family
(GPx; Figure 5b) and superoxide dismutase family (SOD;
Figure 5c) were examined. No effect was seen in GPx expression
levels, but LCA induced a significant dose-dependent increase in
SOD1 transcript levels (Figure 5c). Thus, PC2 eigengenes are
differentially affected by PCN and LCA, and reflect the
antioxidant response elicited by high dose LCA exposure.
To examine the potential biological impact of these transcrip-
tome alterations we undertook Gene Ontology (GO) analysis using
the DAVID suite to identify significantly over-expressed biological
pathways within the subset of transcripts regulated by PCN-alone,
LCA-alone or by both chemicals. Table 4 shows that while the
majority of gene expression changes are exclusive to either LCA or
PCN, with only 9% of transcript changes being shared, at the level
of GO biological pathway terms there is significant overlap (47%),
suggestive of a highly similar biological response to both chemicals;
this also demonstrates the importance of analysis at the pathway
level, rather than just the individual transcript level, as more
information on likely biological effects can be seen. GO
classification terms are divided into five levels, with GO-level 1
representing terms of broadest meaning (e.g. physiological
process), whereas GO-level 5 terms reflect much more precise
definitions of a particular function (e.g. immune response). At the
highest level of GO analysis (GO5), commonly regulated biological
pathways, included those associated with cellular and protein
metabolism, which is consistent with the observed joint inductions
of metabolic enzymes, demonstrated in Figures 1 and 4. For LCA,
there was a specific over-representation of pathways for nitrogen
Figure 1. Induction of PXR-, FXR- and VDR-specific target genes by PCN and LCA. Quadruplicate cultures of primary rat hepatocytes were
exposed to varying concentrations of PCN or LCA for 48 hours. RNA was extracted and target gene expression measured at the transcript level using
TaqMan Q-PCR. Target genes represent those specifically activated by PXR (A), VDR (B) and FXR (C). Statistical analysis against vehicle control was
determined via one-way ANOVA; *=p,0.01, **=p,0.05 and ***=p,0.001.
doi:10.1371/journal.pone.0016703.g001
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secondary bile acid levels, as well as an over-representation of
genes in pathways associated with apoptosis; this latter phenom-
enon probably represents the divergence of LCA along PC2 in the
PCA analysis and shows the response to low-grade cholestatic
insult.
PXR autoregulation insulates endogenous metabolic
processes from external stimuli
A notable feature of the transcript level measurements shown in
Figure 2 is the down regulation of PXR transcript levels by both
chemicals. Such data suggest that PXR-mediated transcriptional
control may be subject to both feed-back and feed-forward control
mechanisms, such that PXR activation both activates target gene
expression and represses PXR expression. To understand the
design principle behind this feed-back/feed-forward system we
constructed two simple in silico models representing PCN
interactions with PXR and its target gene CYP3A1 (Figure 6a),
and LCA interactions with PXR, FXR and VDR, and their target
genes CYP3A1, Fibrinogen B and CYP24 respectively (Figure 6b).
These models were paramaterised with kinetic and quantitative
data derived from published literature and the present study, and
can replicate the effects of PCN and LCA on primary rat
hepatocytes: Down regulation of PXR (PCN and LCA), plus the
up regulation of the nuclear receptor target genes CYP3A1 (PCN
and LCA), FGB (LCA only) and CYP24 (LCA only).
Following demonstration that the models were able to replicate
the biological scenarios, we next examined the impact of PXR-
mediated feed-back loop on these networks. The model was
Table 1. Relative potency for the induction of PXR, VDR and
FXR target genes by PCN and LCA.
Target Gene Activating NR LCA EC50 (mM) PCN EC50 (mM)
CYP3A1 PXR .80 1.460.6
ABCC2 PXR 1067 0.660.4
GSTA2 PXR 35624 0.160.2
CYP24 VDR 564 N.D.
KLK6 VDR 1165 N.D.
Fibrinogen b FXR 1468 N.D.
UGT2B4 FXR 18615 N.D.
N.D. = Not induction observed. Quadruplicate cultures of primary rate
hepatocytes were exposed to varying concentrations of PCN or LCA for
48 hours. RNA was extracted and target gene expression measured at the
transcript level using TaqMan Q-PCR. Dose response curves were fitted using
GraphPad Prism (v5) and EC50 values derived. N.D. = not determined as no
dose response relationship evident.
doi:10.1371/journal.pone.0016703.t001
Figure 2. Nuclear receptor expression in response to PCN and LCA. Quadruplicate cultures of primary rat hepatocytes were exposed to
varying concentrations of PCN or LCA for 48 hours. RNA and protein were extracted and nuclear receptor gene expression measured at the transcript
(A) or protein (B) level using TaqMan Q-PCR or Western blotting, respectively. For protein levels, cells were exposed to either vehicle only (0.1%DMSO;
C), 10 mM PCN or 100 mM LCA as indicated. Antibody fidelity was confirmed a TNT-expressed PXR protein (Lane ‘+’). Statistical analysis against vehicle
control was determined via one-way ANOVA; *=p,0.01, **=p,0.05 and ***=p,0.001.
doi:10.1371/journal.pone.0016703.g002
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feed-back loop, and produces a constant level of PXR regardless of
PCN or LCA exposure (Figure 7). Under stubborn PXR
conditions, no negative feed-back for PXR is present, resulting
in effectively increased PXR levels; such effects result in a
significant increase in CYP3A expression level for any given PCN
exposure, being 162% of the level resulting from 10 mM PCN
exposure under normal conditions (Figure 7a). In comparison, no
alteration is seen in the levels of CYP3A following LCA exposure
under stubborn PXR conditions (Figure 7b). Such a lack of effect
may reflect the significantly lower affinity of LCA for PXR, with
significant effects only being observed at much higher agonist
concentrations. It is also important to note that the action of LCA
as an agonist of VDR and FXR is not affected by the stubborn
PXR condition, with no significant differences observed in the
induction profiles for FGB and CYP24, which reflects the higher
affinities of LCA for these two nuclear receptors.
To examine a potential biological rationale for this PXR
negative feed-back loop we examined the impact of this
attenuation of CYP3A expression on the metabolism of proges-
terone, testosterone and cortisol, all of which are CYP3A
substrates. Simulation of the metabolism of these three steroids
across a full dose response range of PCN or LCA demonstrated no
impact on the Km for testosterone, progesterone or cortisol
metabolism by CYP3A1 in the stubborn PXR system versus the
full network. However, there is a significant impact on the absolute
capacity (Vmax) for these processes following PCN exposure, due
to the lack of decrease in concentration of activated PXR following
PCN exposure in the stubborn PXR models. The relative Vmax in
the stubborn PXR system, as a percentage of the Vmax in the
whole network, was calculated and is shown in Figure 7:
Interestingly, the resultant histogram for PCN treatment is
biphasic, with the lowest point between maxima occurring at the
Kd of PCN for PXR (,1 mM).
To determine if the attenuation of CYP3A gene expression
predicted by the in silico model occurs in reality we next
reproduced the in silico experiments in an in vitro setting: In
addition, all components of the in vitro test system (cell line, target
gene and PXR regulatory regions) were of human origin, allowing
us to examine if the regulatory loop also functioned in the human
context. The Huh7 human hepatoma cell line exhibits low level
expression of PXR under normal conditions, and usually require
addition of a PXR expression plasmid to elicit activation of
reporter gene assays [30], primarily due to altered chromatin
status [31]; they thus represent a near-PXR null system. By
coupling the coding sequence for PXR to its cognate human
proximal promoter (termed pPXR-PXR) it is possible to examine
the role of transcriptional level control of PXR expression on the
activation of downstream target genes such as CYP3A4. It should
be noted that in silico analysis of the human and rat PXR
proximal promoter regions demonstrates a high conservation of
putative transcription factor binding sites, with conserved binding
sites for numerous nuclear receptors including PXR, VDR and
FXR (data not shown).Regulation of pPXR-PXR by PXR ligands
could be demonstrated, with 10 mM PCN eliciting a decrease in
PXR transcript and protein levels to 58% and 41% respectively,
compared to vehicle control; by comparison, no PCN-mediated
alteration in PXR expression levels was observed using the pSG5-
PXR plasmid, where PXR expression is under control of a
heterologous promoter, was observed at either transcript or
protein level (Figure 8a).
We next examined the impact of this on PXR target gene
expression; Huh7 cells were co-transfected with a CYP3A4 SEAP
reporter gene, plus either pSG5-PXR or pPXR-PXR. Cells were
exposed to a concentration curve of PCN between 0.1 mM and
25 mM for 48 hours and then SEAP activity measured. While
PCN is a better agonist of rodent PXR compared to human PXR,
it is still an effective activator of human PXR, as previously
reported. [30]. In the current study, co-transfection with pSG5-
PXR results in an increased CYP3A4 reporter gene expression
compared to basal PXR levels, with a maximal fold increase of 49-
fold over vehicle alone and an EC50=2.461.1 mM (Figure 8b).
Co-transfection with the pPXR-PXR construct also resulted in a
significant increase in CYP3A4 reporter gene expression following
PCN exposure, with a maximal 31.6-fold increase and an
EC50=361.1 mM, but this was significantly lower than the
increase observed with pSG5-PXR. Such data is consistent with a
scenario where PCN-mediated negative regulation of PXR
expression is used to attenuate CYP3A gene expression.
Discussion
Biological response pathways to chemical challenge must exhibit
both sensitivity and robustness: The body must be able to respond
rapidly to either challenge by xenobiotics or changes in
endogenous chemical levels that could result in pathophysiology
(sensitive), while at the same time not allowing this sensitivity to
significantly impact on the endogenous metabolic processes that
utilize the same enzymes (robustness). It is becoming clear that for
this to occur, the body must utilize a network of interactions,
allowing the most efficient response to any given stimulus [3,32].
Table 2. Gene expression changes elicited by PCN and LCA in primary rat hepatocytes.
Drug
Dose
(mM)
FDR
(%) Total genes altered Gene Expression Increased
Gene Expression
Decreased
Predicted False
Positives
PCN 1 10 41 23 18 4
5 9 147 33 114 13
10 6 443 255 188 26
LCA 10 31 10 0 10 3
50 3 253 55 198 8
100 1 356 137 219 4
Quadruplicate cultures of primary rate hepatocytes were exposed to PCN or LCA at the indicated concentrations for 48 hours. RNA was extracted and gene expression
monitored using Affymetrix rat 230 v2 microarrays. Statistical Analysis of Microarrays (SAM) analysis was undertaken to identify statistically significant gene expression
changes (Dose vs medium). False Discovery Rate (FDR) was manually set to provide sufficient gene changes, while limiting the number of predicted false positives.
Numbers of genes altered under each condition are presented for the stated FDR, along with the predicted number of false positives within each group.
doi:10.1371/journal.pone.0016703.t002
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PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16703In the current study we have examined how feed-forward and
feed-back loops are used to control the response to both
endogenous chemicals and xenobiotics, delivering the required
sensitivity and robustness within the network.
The activation of rat transcriptome by the exogenous chemical
PCN has been well studied, both by ourselves and others,
demonstrating a PXR-mediated activation of catabolic and
transport pathways designed to eliminate the stimulating chemical
[32,33,34]. Such a response is logical, given that the chemical is
external by nature and, hence, the body will move to reduce its
concentration to zero through up-regulation of metabolic enzymes
and drug transporters. By comparison, the transcriptomic response
to bile acids is more complicated: At low concentrations, negative
feed-back on bile formation may be sufficient to prevent a build-up
to toxic concentrations. However, as the level of toxic bile acids
approaches that eliciting cholestasis, the body requires a more
frank response, including both an increase in catabolic processes
and protective pathways. This differential response is demonstrat-
ed by the PCA for transcriptome responses to the two ligands,
showing first overlay and then divergence of the trajectories. Given
the relative EC50s for activation of VDR, FXR and PXR by the
two chemicals, at the lower exposure doses it is logical that LCA
target gene-activation is predominantly via VDR, while PCN
activation is through PXR. Given this disparate nuclear receptor
activation it is perhaps surprising that both agents activate a highly
correlated gene expression profile. However, it is well established
that VDR can activate expression of target genes traditionally
associated with PXR through response element sharing [32,35],
and this could explain the overlapping PCA PC1 trajectories,
which are primarily determined by activation of metabolic genes.
The activation of a general metabolic response, combined with the
activation of VDR- and FXR-specific target genes, should be
sufficient to cause a return to homeostasis at these lower
concentrations of LCA. However, if the concentration of LCA
continues to rise, the percentage activation of PXR will also
increase, leading to increased metabolic activation of, for example,
CYP3A1, plus the activation of specific target genes geared
towards meeting the response to cholestatic injury.
A novel finding of the current work is the activation of
expression for the metallothionein 1a and 2 genes by LCA. Such a
response can almost certainly be attributed to the oxidative stress
caused during cholestasis [36]. FXR knockout mice show an
increased susceptibility to bile acid-induced ROS damage,
suggesting that activation of these genes is, at least in part, under
the control of FXR [37]. However, in the current study, activation
of these protective gene products occurs at higher LCA
concentrations, when PXR will be significantly activated. Zilliacus
and colleagues have previously suggested that MTs can be
regulated by PXR [38], and the data presented herein is consistent
with such a scenario. We would therefore postulate that PXR
activation by LCA becomes significant as LCA concentration
approaches that eliciting pathophysiology, resulting in the
production of protective mechanisms to reduce the associated
oxidative stress, namely increased MT1a and 2 and SOD1
transcript levels.
Taken together these findings would suggest that the regulation
of bile acid homeostasis in rats is through the action of the PXR,
VDR and FXR nuclear receptors working as a partnership of
complimentary pathways, adjusting the pattern of gene expression
for extent of divergence from bile acid homeostasis, aiming to
ensure healthy physiology. Such a interaction is demonstrated well
in knockout mice, with FXR and PXR individual gene knockouts
showing a reduced, but still strong, response to bile acid loading
[39], whereas the PXR/FXR double knockout mice show a poor
response to bile loading [40]. This poor response indicates that
while CAR, LXR and VDR are all implicated in small areas of
bile acid biosynthesis, FXR and PXR are the dominant receptors
responsible for control in this system [40].
As stated above, one level at which refinement of biological
response to chemical stimulus can be achieved is through the
interaction of nuclear receptors signalling, via auto- or trans-
regulatory loops, or through competition for ligands and/or
response elements. Herein, we demonstrate that PXR is under
control of a feed-back loop, with both PCN and LCA reducing
Figure 3. PCN and LCA activate divergent transcriptome profiles in a dose-dependent manner. Quadruplicate cultures of primary rat
hepatocytes were exposed to PCN or LCA at the indicated concentrations for 48 hours. RNA was extracted and gene expression monitored using
Affymetrix rat 230 v2 microarrays. Statistically significant transcript changes were identified by SAM analysis, and the analysed by PCA using MVSP.
doi:10.1371/journal.pone.0016703.g003
Table 3. Eigengenes for PCA of LCA and PCN-treated
hepatocytes.
Affy ID Gene Name PC1 PC2
1367655_at thymosin, beta 10 0.534
1370952_at GSTM2 0.297
1368180_s_at GSTA3 0.236
1394109_at thrombospondin 2 0.22
1370698_at UGT2B17 0.197
1368397_at UGT2B4 0.185
1380865_at Transcribed locus 0.156
1387955_at UGT2B5 0.145
1367973_at chemokine (C-C motif) ligand 2 0.143 20.215
1387949_at CYP2C22 0.122
1372297_at GSTA4 0.12
1368718_at ALDH1A4 0.114
1368497_at ABCC2 0.105
1386886_at CD164 molecule, sialomucin 20.116
1388506_at Desmoplakin 20.121
1398846_at eIF-5 20.127
1386902_at voltage-dependent anion channel 3 20.129
1387777_at integrin linked kinase 20.137
1388236_x_at RT1-CE1 20.137
1370277_at SLC25A3 20.294
1371237_a_at metallothionein 1a 0.46
1388271_at metallothionein 2A 0.344
1393236_at RIO kinase 3 20.189
1370281_at FABP5 20.196
1372687_at cysteine-rich C-terminal 1 20.357
Quadruplicate cultures of primary rate hepatocytes were exposed to varying
concentrations of PCN or LCA for 48 hours. RNA was extracted and gene
expression monitored using Affymetrix rat 230 v2 microarrays. Significantly
altered transcript levels were determined via SAM analysis, then further
analysed using PCA. Eigengenes describing the variation along principle
component 1 (PC1) and 2 (PC2) are indicated, along with the eigenvalue for
each eigengene against its primary component.
doi:10.1371/journal.pone.0016703.t003
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agonist present; however, activation of this feed-back loop only
occurs at pathophysiological concentrations for LCA. Such data is
consistent with previous observations that over-expression of PXR
in vitro results in a decrease in PXR reporter gene activity [21],
with these latter experiments being supportive for such regulation
occurring at the transcriptional level. However, Maglich et al.
observed a 2.7-fold increase in PXR transcript levels in mice
following exposure to PCN, which was ablated in a PXR knockout
animal [41]. Whereas both findings are consistent with a PXR-
mediated regulation of PXR transcript levels, they differ in the
directionality of this change. The inconsistency of these findings
may be a product of the differing test systems, primary rat
hepatocytes versus mouse in vivo, or the exposure period, 48 hours
versus 28 hours. It should be noted that the findings presented
herein are supported by changes at the protein level as well,
demonstrating the observed transcriptome level effects are
translated to the proteome. Whereas such data is consistent with
the presented hypothesis, it should be noted that alternate
hypothesis may be envisaged; for example, ligand stimulation
might increase targeting of the activated receptor molecule to the
proteosome, as seen with other nuclear receptors [42]. Such an
effect would also decrease protein levels, but not via a
transcriptional route. Given the transcriptional-level effects
observed both herein and by Maglich et al., it is likely that such
a mechanism would be complimentary, not alternate, to any
transcriptional level control; indeed, the altered protein levels
resulting from degradation rate increases might actually be the
driver for an alteration in transcription rates, but further work
would be required to evaluate this. In addition, it should be noted
that no measurement of potential post-translational modifications
have been undertaken, which could further modulate the activity
of a liganded nuclear receptor [43].
The decrease in PXR protein levels observed herein could serve
two important processes: First, ensuring that the levels of free
agonist remain high, potentially increasing interaction of the
agonist with other nuclear receptors. Second, a reduction in the
total amount of PXR protein will reduce the total amount of
activated PXR protein, as this is a function of receptor occupancy;
such a reduction in activated PXR could impact upon the
expression level of downstream target genes, such as CYP3A1, as
proposed herein. This would attenuate PXR target gene induction
at higher agonist concentrations, preventing an over-response of
the biological system to hyper-stimulation. Given that order of
nuclear receptor activation by LCA is VDR<FXR..PXR, then
the first scenario is unlikely to be important, as at concentrations of
LCA where PXR negative feed-back becomes significant, receptor
occupancy for VDR and FXR is already approaching maximal.
We therefore postulate that the second scenario is more probable,
whereby PXR negative feed-back is utilized to attenuate PXR-
mediated activation of target genes at higher agonist concentra-
tions. Such a hypothesis is supported by the in vitro data
demonstrating attenuation of CYP3A induction by PCN, and by
the in silico simulation demonstrating significantly higher turnover
rates for three endogenous CYP3A substrates, testosterone,
progesterone and cortisol, when the feed-back loop is removed.
This data is highly supportive of the notion that the PXR feed-
back loop is required for the robustness of steroid homeostasis in
the case of steroids that are CYP3A substrates, and is logical with
regard to cellular energetic position, as it is far more efficient to
attenuate degradation of these steroids rather than increase de
novo synthesis to compensate for increased degradation. Interest-
ingly, this attenuation appears to be biphasic, with maximal
attenuation occurring at the Kd for the agonist, although the
rationale for this is unclear. It should also be noted that this
autoregulatory loop may not always be activated, and indeed we
Figure 4. Transcript expression levels of PC1 eigengenes. Quadruplicate cultures of primary rat hepatocytes were exposed to varying
concentrations of PCN or LCA for 48 hours. RNA was extracted and transcript levels for PC1 eigengenes determined using TaqMan Q-PCR. Statistical
analysis against vehicle control was determined via one-way ANOVA; *=p,0.01, **=p,0.05 and ***=p,0.001.
doi:10.1371/journal.pone.0016703.g004
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endogenous ligands, with activation of PXR by some glucocorti-
coids, progestins and androgens not appearing to activate this
feed-back loop (unpublished data). This minimal/absent use of the
PXR feed-back loop by endogenous agonists may be logical, as
concentrations of endogenous ligands high enough to significantly
activate PXR would only occur in pathophysiological conditions
when it would be important to return to homeostasis as soon as
possible and not limit the rate of CYP3A1-mediated degradation.
It is thus tantalizing to suggest that PXR can sense those ligands
that may impact upon endogenous metabolism and activate the
autoregulatory loop, while disengage the loop for endogenous
chemicals to allow a more efficient return to homeostasis. Such a
bipartite response could reflect the recruitment of differing co-
regulators to the agonist-PXR complex, either allowing or
preventing repression of PXR gene expression. Regulation of
PXR by other nuclear receptors has already been established
[12,14], although the molecular mechanisms for such interactions
Figure 5. Transcript expression levels of PC2 eigengenes. Quadruplicate cultures of primary rat hepatocytes were exposed to varying
concentrations of PCN or LCA for 48 hours. RNA was extracted and transcript levels for PC2 eigengenes (A), plus other oxidative stress response
genes (B+C) determined using TaqMan Q-PCR. Statistical analysis against vehicle control was determined via one-way ANOVA; *=p,0.01,
**=p,0.05 and ***=p,0.001.
doi:10.1371/journal.pone.0016703.g005
Table 4. LCA and PCN activate different target genes, but
markedly overlapping GO biological processes.
Direction Gene Expression GO Biological Process
of Regulation
PCN
Alone
LCA
Alone Both
PCN
Alone
LCA
Alone Both
UP 272 150 24 13 6 14
DOWN 219 272 69 7 9 18
Quadruplicate cultures of primary rate hepatocytes were exposed to PCN or
LCA for 48 hours. RNA was extracted and gene expression monitored using
Affymetrix rat 230 v2 microarrays. Gene expression number relates to those
identified as significantly altered via SAM analysis; functional annotation
clustering was undertaken on these identified genes using DAVID, with GO
biological process 3–5 as the search term.
doi:10.1371/journal.pone.0016703.t004
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PLoS ONE | www.plosone.org 10 February 2011 | Volume 6 | Issue 2 | e16703are not always clear, with the exception of PPARa [14].
Glucocorticoid-mediated induction of PXR expression is likely to
be mediated through the glucocorticoid receptor, with a GRE
present within the PXR proximal promoter [14]. However, no
PXRE exists within the PXR proximal promoter; instead it is
tempting to postulate that any such regulation would occur
through interaction with the VDREs present within this regulatory
region, as PXR has already been shown to be able to function in
this manner [44]: However, further work is required to confirm
such speculation.
In summary, the current study has demonstrated that PXR not
only acts as a xenosensor in the classical sense, but also potentially
acts as an ‘endosensor’, allowing it to coordinate responses to
chemical exposure in a tailored fashion dependent upon the nature
of the chemical challenge and its likely impact on body
homeostasis.
Figure 6. In silico models of PCN and LCA Interactions within the cell. The generated models are based upon known and presumed
interactions of (A) PCN and (B) LCA with nuclear receptors, and was generated using CellDesigner (v4.0.1; Systems Biology Institute, http://
celldesigner.org/index.html). Each individual chemical or protein is identified as a species (s1.....sn), while interactions between species are identified
as reactions (r1....rn). The generated models (closed squares) were able to reproduce in vitro (open squares) observed agonist-mediated suppression
of PXR expression, and activation of CYP3A1, CYP24 and Fibrinogen B gene expression by agonist-activation of PXR, VDR and FXR respectively.
doi:10.1371/journal.pone.0016703.g006
Figure 7. In silico simulation of the role of PXR autoregulation in the robustness of steroid biochemistry. The described in silico models
were used for simulation as complete models (filled squares), or with the PXR autoregulatory feed-back loop disabled (stubborn PXR; open squares)
following exposure to PCN (A) and LCA (B). Simulated protein levels of PXR, its target gene CYP3A1, and the Vmax against CYP3A substrates of the
stubborn PXR system as a percentage of the complete model derived for a dose range of each agonist. In addition, protein levels of the VDR and FXR
target genes CYP24 and Fibrinogen B, respectively, are also presented for LCA.
doi:10.1371/journal.pone.0016703.g007
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Ethics Statement
All animal experiments described herein were undertaken in full
compliancewiththerelevantsections of theUKGovernmentScientific
Procedures Act (1986) for the use of animals in experimentation.
Termination of rats for primary hepatocyte preparation was covered
by the general project licence 40/2892 held by AstraZeneca Safety
Assessment, UK, which was approved by the UK Government Home
Office Animal Procedures Committee under A(SP)A 1986.
Chemicals
PCN and LCA were of cell culture grade and purchased from
Sigma Chemical Co. (St. Louis, MO). Unless otherwise stated all
other chemicals were of molecular biology grade and obtained
from Sigma Chemical Co. (St. Louis, MO).
Cell Culture
Primary rat hepatocytes were isolated from AZ Sprague-Dawley
rats and grown in sandwich culture system using RPMI medium,
supplemented with 10% foetal bovine serum, 50 mg/ml pen/strep
and 1610
27 M human insulin. Cells were initially plated at a
density of 1610
5 cells/cm
2 for 4 days; at this point functioning bile
canaliculi were formed, confirmed using the ABCC2-specific
substrate carboxydichlorofluroscein, which will only be transport-
ed in correctly polarised cells [26] (data not shown). Following
formation of functioning cannaliculi, cells were dosed daily to
varying concentrations of PCN (1, 2, 5, 8, 10 mM), LCA (10, 20,
50, 80, 100 mM) or vehicle control (0.1% DMSO). Following
48 hours of exposure, cells were lyzed and RNA isolated and
purified using the RNAqueous-4PCR kit (Ambion, Austin, TX),
and quantified using a Nanodrop Agilent 2100 Bioanalyser.
Compound mediated toxicity was assessed by LDH assay, and was
shown to be non-significant at all concentrations tested (data not
shown).
The Huh7 human hepatocellular carcinoma cell line [45] was a
kind gift from Dr Steve Hood (GSK, Ware, UK). All cells were
routinely cultured in 75 cm
2 vented tissue culture flasks (Nunc,
UK) using minimal essential medium with Earle’s salts supple-
mented with 1% non-essential amino acids, 2 mM L-glutamine,
100 U/ml penicillin, 100 mg/ml streptomycin and 10% foetal
bovine serum. In order to maintain phenotypic consistency, Huh7
cells were only used for three weeks (approximately 5 passages)
following recovery from liquid nitrogen.
DNA Microarray and Analysis
Total RNA was processed and labelled for microarray analysis
using the One cycle target labelling and control reagents kit
Figure 8. Negative feedback on PXR expression attenuates induction of CYP3A4 expression in vitro. Quadruplicate cultures of Huh7
cells were transfected with a CYP3A4 reporter gene alone, or with pSG5-PXR, pPXR-PXR. Following 24 hours incubation, cells were exposed to varying
doses of PCN for 48 hours, as indicated, and then analysed: PXR transcript and protein levels are shown in (A), while reporter gene activity shown in
(B). Statistical analysis against vehicle control was determined via one-way ANOVA; *=p,0.01, **=p,0.05 and ***=p,0.001.
doi:10.1371/journal.pone.0016703.g008
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Affymetrix rat 230 v2 GeneChip set, representing over 30,000
transcripts including approximately 28,000 well substantiated rat
genes.
The raw data generated from the microarray was first
normalised using the Affymetrix algorithm, which allows reliable
comparison of multiple arrays through minimising differences of
non-biological origin. All data was produced in a MIAME-
compliant format [46], with the normalised output from the
microarray presented as File S1.
Next, the SAM (Significance Analysis of Microarrays) package
(http://www-stat.stanford.edu/,tibs/SAM/) was used to identify
significantly altered gene expressions, and generate false discovery
rate (FDR) values for the analysis. The SAM package offers the
advantage over other microarray analysis tools in that it does not
presume equal variance or independence of genes (or both),
scenarios that are often violated in biological systems [47].
Heatmaps from the SAM output were generated using Cluster
3.0 [48] and visualised using Java TreeView [49], while Principle
Component Analysis was undertaken using MVSP (Kovach
Computing Service, Anglesey, UK).
To examine the potential impact on biological pathways of the
identified gene expression changes the DAVID software suite
(http://david.abcc.ncifcrf.gov/home.jsp) was used to undertake
functional annotation clustering, whereby GO identifiers that are
statistically over-represented are clustered according to their
biological functions [50]. The full output from the microarray
experiment has been deposited with public GEO database (www.
ncbi.nlm.nih.gov/geo).
Transcript level measurement
Specific primers and TAMRA/FAM dual labelled probe sets
were designed against all target genes using the Primer Express
software (Applied Biosystems, Warrington, UK) and were
purchased from Eurofins MWG (Wolverhampton, UK): Sequenc-
es for all probe/primer sets are presented as File S2.
Total RNA was treated with RNase-free DNase (Promega,
Southampton, UK) to remove genomic contamination. Reverse
transcription was primed with random hexamers and carried out
by Superscript II (Invitrogen) as per the manufacturer’s instruc-
tions. To ensure that DNase treated samples were free from
genomic contamination an RT- control (lacking enzyme) was
carried out for every RNA sample. cDNA amplified using
TaqMan Universal PCR Master Mix with 400 nM primers and
200 nM fluorogenic probe in a total reaction volume of 25 ml: In
general, cDNA generated from 50 ng input total RNA was used
per reactions, with the exception of 18 s detection, where cDNA
derived from 50 pg input total RNA was used. Quantitative
polymerase chain reaction (Q-PCR) reactions were run on the
ABI7000 SDS instrument and quantitation was carried out using
the ABI proprietary software against a standard curve generated
from human genomic DNA (Promega), and normalised against
18 s rRNA expression levels.
Protein level measurement
Primary rat hepatocytes (Invitrogen) or Huh7 cells were seeded
at 2.4610
5 cells/cm
2 in 25 cm
2 flasks and treated as described
above. Following 48 hours of exposure to vehicle, PCN or LCA
total protein was extracted in RIPA buffer (1xPBS, 1% Nonidet
P40, 0.5% sodium deoxycholate, 0.1% SDS, protease inhibitor
cocktail).
Total protein extracts (10 mg per lane) were resolved on 12%
SDS-polyacrylamide gels and then transferred electrophoretically
to Hybond ECL nitrocellulose membranes (Amersham Bioscienc-
es, Little Chalfont, Bucks, UK). Membranes were blocked (1 hour)
in 5% fat free dried milk and then probed with primary antibodies
against human PXR (SAB2101636, 1:350; Sigma-Aldrich) or a-
actin (sc1616, 1:500; Autogen Bioclear), followed by anti-rabbit
IgG (sc2030, 1:10000; Autogen Bioclear) or anti-goat IgG (sc
2020, 1:20000; Autogen Bioclear) respectively. Bound antibodies
were visualised using enhanced chemiluminescence reagents
according to the manufactures instructions (Amersham Bioscienc-
es).
Reporter gene assay
Huh7 cells were seeded into 96-well plates (Nunc International,
Leicestershire, UK) at a concentration of 10,000 cells/well and
incubated at 37uC for 24 hrs in a humidified container for
attachment. FuGENE 6-mediated DNA co-transfections, using
CYP3A4-XREM reporter gene construct [30], plus an expression
plasmid for PXR, either under the control of a minimal promoter
or the cognate human 2.2 kb PXR proximal promoter. Following
24 hours incubation, cells were exposed to vehicle or drug and
allowed to proceed for 48 hours, and secretory alkaline phospha-
tase (SEAP) activity measured: Briefly, aliquots of cell culture
medium (25 ml/well) were transferred into 96-well optiplates
(Canberra Packard, UK), endogenous alkaline phosphatase
activity deactivated by heat-treatment and then SEAP activity
assayed using the AURORA system (ICN, Thame, UK),
according to the manufacturer’s protocol. Chemiluminescent
output was measured using a LumiCount automated plate reader
(Canberra Packard, UK).
SEAP activity following 48 hours culture was calculated for
both reporter constructs and blank, control, plasmid, and a fold
induction relative to vehicle control calculated.
In silico Modelling
In silico models were generated using CellDesigner (v4.0.1;
Systems Biology Institute, http://celldesigner.org/index.html), a
graphical front-end for creating process diagrams of biochemical
networks in systems Biology Markup Language (SBML; [51]).
Each individual chemical or protein is identified as a species
(s1.....sn), while interactions between species are identified as
reactions (r1....rn). For each reaction, a kinetic term is included,
detailing the mathematics underlying the interaction of the species:
A full diagrammatic representation, plus paramaterisation values
for each model are presented as File S3.
Supporting Information
File S1 Raw Gene Array Output. Quadruplicate cultures of
primary rat hepatocytes were exposed to PCN or LCA at the
indicated concentrations for 48 hours. RNA was extracted and
gene expression monitored using Affymetrix rat 230 v2 micro-
arrays. Fluorescent output for each probe on each array is
presented, following normalisation using the Affymetrix algorithm.
(XLS)
File S2 TaqMan Probe sets. Specific primers, plus TAMRA/
FAM dual labelled probes, were designed against the indicated
RefSeq for each target gene using the Primer Express software
(Applied Biosystems, Warrington, UK). Probe primer sets were
designed to cross an intron-exon boundary, with design param-
eters set as defaults for the software.
(DOC)
File S3 Model Parameters. In silico models for both PCN-
and LCA-response networks were generated using CellDesigner
(v4.0.1), represented in the Systems Biology Graphical Notation
Negative Feedback in PXR Signalling
PLoS ONE | www.plosone.org 13 February 2011 | Volume 6 | Issue 2 | e16703(SBGN) images. Expression levels of individual species, kinetic
descriptions of reactions, plus initial state values for each network
are also provided.
(DOC)
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